Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers

Experimental and Molecular Medicine

Volumn 43, Issue 4, 2011, Pages 216-222

  Lee, He Jin ^a,c   Baek, Sung Min ^b,c   Ho, Dong Hwan ^b,c   Suk, Ji Eun ^b,c   Cho, Eun Duk ^a,c   Lee, Seung Jae ^b,c  

^a School of Medicine

^b Department of Biomedical Science and Technology ^*

^c Konkuk University   (South Korea)

Author keywords

Alpha synuclein; Amyloid; Dopamine; Parkinson's disease; Protein aggregation; Secretion

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; MONOMER; NONFIBRILLAR ALPHA SYNUCLEIN OLIGOMER; OLIGOMER; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BETA SHEET; CELL LEVEL; CELL VACUOLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DOPAMINERGIC NERVE CELL; FIBER; HUMAN; HUMAN CELL; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; PROTEIN SECRETION;

EID: 79955660630     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.3858/emm.2011.43.4.026     Document Type: Article

References (28)

1. Bisaglia M, Mammi S, Bubacco L. Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with {alpha}synuclein. J Biol Chem 2007;282:15597-605
2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211
3. Burke WJ, Kumar VB, Pandey N, Panneton WM, Gan Q, Franko MW, O'Dell M, Li SW, Pan Y, Chung HD, Galvin JE. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol 2008; 115:193-203
4. Cappai R, Leck SL, Tew DJ, Williamson NA, Smith DP, Galatis D, Sharples RA, Curtain CC, Ali FE, Cherny RA, Culvenor JG, Bottomley SP, Masters CL, Barnham KJ, Hill AF. Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J 2005;19:1377-9
5. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 2001;294: 1346-9
6. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee SJ. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 2009;106: 13010-5
7. Fahn S, Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 2004;1:139-54
8. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006;7:306-18
9. Galvin JE. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra. Acta Neuropathol 2006;112:115-26
10. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001;2:492-501
11. Jang A, Lee HJ, Suk JE, Jung JW, Kim KP, Lee SJ. Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. J Neurochem 2010;113:1263-74
12. Kim C, Lee SJ. Controlling the mass action of alphasynuclein in Parkinson's disease. J Neurochem 2008; 107:303-16
13. Kim YS, Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med 2006;38:333-47
14. Lee HJ, Shin SY, Choi C, Lee YH, Lee SJ. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem 2002;277:5411-7
15. Lee HJ, Khoshaghideh F, Patel S, Lee SJ. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 2004;24:1888-96
16. Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci 2005;25:6016-24
17. Lee HJ, Suk JE, Bae EJ, Lee JH, Paik SR, Lee SJ. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol 2008;40: 1835-49
18. Lee HJ, Suk JE, Patrick C, Bae EJ, Cho JH, Rho S, Hwang D, Masliah E, Lee SJ. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem 2010;285:9262-72
19. Lee SJ. Origins and effects of extracellular alpha-synuclein: implications in Parkinson's disease. J Mol Neurosci 2008;34: 17-22
20. Leong SL, Pham CL, Galatis D, Fodero-Tavoletti MT, Perez K, Hill AF, Masters CL, Ali FE, Barnham KJ, Cappai R. Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation. Free Radic Biol Med 2009;46:1328-37
21. Li HT, Lin DH, Luo XY, Zhang F, Ji LN, Du HN, Song GQ, Hu J, Zhou JW, Hu HY. Inhibition of α-synuclein fibrillization by dopamine analogs via reaction with the amino groups of α-synuclein. Implication for dopaminergic neurodegeneration. FEBS J 2005;272:3661-72
22. Li J, Zhu M, Manning-Bog AB, Di Monte DA, Fink AL. Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. Faseb J 2004;18:962-4
23. Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH, Sulzer D. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009;62:218-29
24. Norris EH, Giasson BI, Ischiropoulos H, Lee VM. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J Biol Chem 2003;278:27230-40
25. Pham CL, Leong SL, Ali FE, Kenche VB, Hill AF, Gras SL, Barnham KJ, Cappai R. Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner. J Mol Biol 2009;387:771-85
26. Presgraves SP, Ahmed T, Borwege S, Joyce JN. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists. Neurotox Res 2004;5:579-98
27. Uversky VN. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. J Neurochem 2007;103: 17-37
28. Volles MJ, Lansbury PT Jr. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in parkinson's disease. Biochemistry 2003;42:7871-8